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A novel enhancer regulates MGMT expression and
promotes temozolomide resistance in glioblastoma
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Lihong He4, Zeng Hu4, Ian F. Parney5, Fredric B. Meyer5, Caterina Giannini6, Jann N. Sarkaria4 & Zhiguo Zhang2
Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade,
but its treatment benefits are limited by acquired resistance, a process that remains
incompletely understood. Here we report that an enhancer, located between the promoters of
marker of proliferation Ki67 (MKI67) and O6-methylguanine-DNA-methyltransferase
(MGMT) genes, is activated in TMZ-resistant patient-derived xenograft (PDX) lines and
recurrent tumor samples. Activation of the enhancer correlates with increased MGMT
expression, a major known mechanism for TMZ resistance. We show that forced activation
of the enhancer in cell lines with low MGMT expression results in elevated MGMT
expression. Deletion of this enhancer in cell lines with high MGMT expression leads to a
dramatic reduction of MGMT and a lesser extent of Ki67 expression, increased TMZ sen-
sitivity, and impaired proliferation. Together, these studies uncover a mechanism that reg-
ulates MGMT expression, confers TMZ resistance, and potentially regulates tumor
proliferation.
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G lioblastoma (GBM) is the most common and aggressiveprimary brain tumor. Despite current therapy, mediansurvival for GBM patients is ~15 months1. Temozolomide
(TMZ) has been the standard chemotherapy for newly diagnosed
GBM for more than a decade2. However, almost all patients
eventually develop resistance. Moreover, recurrent tumors in
general are more aggressive than primary tumors. Therefore,
there is a critical need to understand how TMZ resistance is
acquired and whether there is any connection between TMZ
resistance and tumor aggressiveness.
While multiple factors have been associated with TMZ resis-
tance, expression of O6-methylguanine-DNA-methytransferase
(MGMT) remains a major cause3. MGMT is a DNA repair
protein, which removes the cytotoxic O6-methylguanine (O6MG)
DNA lesions generated by TMZ, and high MGMT expression in
cells is mechanistically linked to robust TMZ resistance. MGMT
expression can be silenced by the methylation of a promoter/
enhancer (P/E) region, which contains a promoter and a 59 bp
cis-acting enhancer element that spans the first exon–intron
boundary of MGMT gene4. Several large cohort studies indicate
an association between DNA methylation of the (P/E) region and
favorable outcomes of TMZ treatment5,6. This observation led to
the hypothesis that MGMT inhibition may be a plausible strategy
for sensitizing TMZ therapy in MGMT-expressed tumors7–9.
However, combinations of TMZ with MGMT inhibitors such as
O6-benzylguanine (O6BG), a synthetic derivative of guanine that
can inhibit MGMT but was developed before the clone of the
MGMT gene, resulted in enhanced hematologic toxicities, a
reduced therapeutic window and no clinical benefit compared to
TMZ alone10,11. Moreover, there is discordance between pro-
moter methylation status and MGMT protein expression in GBM
with wild-type MGMT coding sequence12–14. For instance, high
levels of MGMT expression were detected in samples with DNA
methylation at the P/E region. These observations indicate that, in
addition to promoter methylation, other factors may regulate
MGMT expression and confer TMZ resistance, and that identi-
fication of these additional mechanisms of MGMT regulation
may provide a strong rationale for the development of a new class
of drugs for this deadly disease.
Besides DNA methylation, posttranslational modifications on
histone proteins also regulate gene expression. Distinct histone
modifications are found at gene regulatory elements important
for gene transcription15. For example, H3K4me3 is enriched at
promoters of active genes, whereas H3K27me3 is enriched at
promoters of repressed genes. In addition to promoters, enhan-
cers, a DNA element that promotes the gene transcription via a
long-range interaction with their cognate promoters, are sur-
rounded by nucleosomes with distinct histone modifications16.
Based on the histone modifications of surrounding nucleosomes,
enhancers in general can be classified as active, primed, or poised
ones. Active enhancers are typically surrounded by nucleosomes
with H3K4me1 and H3K27ac17, with the levels of H3K27ac
correlating positively with enhancer activity. Primed enhancers
are marked with nucleosomes with H3K4me1, whereas poised
enhancers are marked by both H3K4me1 and the repressive mark
H3K27me318. Here, we report the identification of a distal
enhancer, which we call the K-M enhancer that is situated
between MKI67 and MGMT promoters and is 560 kb away from
the MGMT promoter. Ki67 is a well-known cell proliferation
mark for many tumor types including GBM19. In other cancers,
such as breast cancer20–22, the fraction of cells staining positively
for Ki67 is associated with increased proliferation and adverse
clinical outcome. While controversial, high Ki67 staining is
associated with elevated proliferation and poor prognosis of brain
tumors in some of these studies23–26. We show that the K-M
enhancer activates MGMT gene expression even in the presence
of a hypermethylated promoter. Moreover, deletion of the
enhancer results in reduced expression of MGMT, but to a lesser
extent on Ki67 expression. Finally, brain tumor cells lacking the
enhancer are sensitive to TMZ and exhibit reduced growth rate.
Together, these studies uncover a previously unknown mechan-
ism regulating both TMZ resistance and the proliferation of GBM
cells.
Results
Enhancer marks are altered in a TMZ-resistant GBM line. To
investigate the epigenetic changes that occur during tumor
recurrence, we used a patient-derived xenograft (PDX) model
previously described14. The GBM12 xenograft line derived from a
newly diagnosed MGMT hypermethylated tumor was used to
generate TMZ-resistant sublines. For this, multiple mice with
flank tumors generated from GBM12 were treated with three
cycles of TMZ or placebo. Two tumor sublines, a TMZ-sensitive
tumor from the placebo group named GBM12 5199 (5199) and a
TMZ-resistant tumor from the TMZ treatment group named
GBM12 3080 (3080) were obtained (Fig. 1a). Similar to the ori-
ginal hypermethylated GBM12 tumor, the placebo-treated 5199
line had low MGMT protein expression and was highly suscep-
tible to TMZ. In contrast, the TMZ-resistant 3080 line had robust
MGMT expression despite of the presence of MGMT promoter
methylation (Fig. 1b, c). These results suggest that other
mechanisms are driving MGMT expression even in the presence
of the MGMT promoter hypermethylation.
In addition to DNA methylation, histone modifications also
play an important role in the regulation of gene expression14,27.
To test whether changes in histone modifications were associated
with elevated MGMT expression in 3080, we analyzed histone
modifications for active enhancers (H3K4me1 and H3K27ac),
promoters (H3K4me3 and H3K9ac), or gene bodies (H3K36me3)
and repressed mark (H3K9me3) in 5199 and 3080 sublines using
chromatin immunoprecipitation coupled with next-generation
sequencing (ChIP-seq) (Fig. 1d–g, Supplementary Fig. 1 and
Supplementary Table 1). We found the global levels of H3K4me3
and H3K9ac at promoters and H3K36me3 at gene bodies were
similar between 5199 and 3080. Interestingly, although global
H3K4me1 and H3K27ac levels were quite similar between these
two sublines based on western blot analysis (Fig. 1b), their
enrichment at enhancer regions was reduced in the 3080 line
compared to the 5199 line, though this difference needs to be
corroborated by further tests using spiked-in internal controls
(Fig. 1d, e). Moreover, the level of H3K9me3 was increased at the
transcription starting sites (TSS) in the TMZ-resistant 3080
compared to the TMZ-sensitive 5199 (Supplementary Fig. 1). We
note a previous report showing that heterochromatin reorganizes
and H3K9me2/3 increases in GBM cells treated with TMZ28.
These results suggest that two histone modifications at enhancer
regions are susceptible to alterations during the acquisition of
TMZ resistance.
Activated enhancers are characterized by increased H3K27ac
levels surrounding the enhancers and will lead to elevated
transcription of their target genes. To classify enhancers that are
altered in the 3080 compared to 5199 sublines, we performed
unsupervised clustering analysis based on the changes of
H3K4me1 and H3K27ac levels and the correlations with the
expression change of genes close to each of these putative
enhancers (Fig. 1h). In comparison to 5199, we observed that
most enhancers exhibited reduced levels of H3K27ac and
H3K4me1 in 3080, consistent with our previous observation that
these two marks were reduced at enhancer regions in the 3080
line compared to 5199 line. A small group of enhancers (1141
Group-1 enhancers) exhibited increased H3K27ac and H3K4me1
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in the 3080 line, suggesting that this group of enhancers is
activated in the TMZ-resistant line. Moreover, the activation of
this group of enhancers correlated with increased expression of
nearby genes. Pathway analysis of nearby genes of this group of
enhancers indicated that genes involved in gliomagenesis and
cancer drug resistance are enriched (Fig. 1i). Interestingly,
MGMT, a key driver of TMZ resistance29, was one of the top
10 genes in this list that shows significant changes in gene
expression (Table 1 and Supplementary Data 1). These results
suggest that a subgroup of enhancers were activated in the 3080
line, at least one of which contributes to TMZ resistance.
MGMT is regulated by a novel enhancer. Inspection of
H3K4me1, H3K27ac, H3K4me3, and H3K36me3 ChIP-seq peaks
close to the MGMT gene locus revealed that H3K36me3 within
the MGMT gene body and H3K4me3 in the promoter region of
MGMT were enriched in the 3080 line compared to 5199 line,
consistent with the increased MGMT transcription in the 3080
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Fig. 1 Enhancer marks are altered in a TMZ-resistant PDX line. a Schematic diagram for the development of 5199 and 3080 xenograft lines from parental
GBM12 cells. Mice with GBM12 flank tumors were treated with placebo or three cycles of TMZ (50mg/kg/d for 5 days every 28 days). Tumors were
dissected after reaching >1500mm3. The xenograft subline established from placebo-treated tumor was named 5199 and that from TMZ-treated tumor
was named 3080. b Analysis of MGMT, H3K27ac and H3K4me1 levels in protein lysates of 5199 and 3080 xenograft tissues by western blotting. α-tubulin
and histone H3 was used as a loading control for cytosolic proteins and nuclear proteins, respectively. c Analysis of MGMT promoter methylation in 5199
vs. 3080 xenograft lines by MS-PCR. Universal methylated DNA was used as positive control and normal human brain DNA was used as negative control.
d–g Aggregate plots showing the average ChIP-seq reads distribution for the various histone marks: H3K4me1 (d) and H3K27ac (e) ChIP-seq reads
surrounding the published enhancer regions; H3K4me3 (f) ChIP-seq reads surrounding transcription start site (TSS); H3K36me3 ChIP-seq reads across
gene bodies (g). TTS: transcription termination site. h Heat maps showing cluster analysis, based on H3K27ac and H3K4me1 alterations, and expression
change for genes closest to each genomic locus. The ratio of ChIP-seq reads density (3080 reads/5199 reads) for H3K4me1 and H3K27ac was calculated
and subsequently analyzed by k-means cluster analysis. Changes in gene expression were calculated as RNA-seq reads ratio (3080 reads/5199 reads).
Color scale represents decreased (green) and increased (magenta) signal intensity (intensity= log23080 reads5199 reads ). i Bar graphs showing ingenuity pathway
analysis for Group-1 genes. Pathways with a p value <0.05 are presented
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line (Fig. 2a). Moreover, we detected an increase in H3K4me1 and
H3K27ac enrichment in the 3080 line compared to 5199 line at a
region 560 kb away from the MGMT promoter, suggesting that
this region may be a putative enhancer that can activate MGMT
expression. Because this putative enhancer localized in an inter-
genic region between MKI67 gene and MGMT gene, we named
this putative enhancer K-M enhancer. By analyzing immuno-
precipitated chromatin DNA using four pairs of primers,
including three pairs (PE1-3) spanning the putative K-M
enhancer region and a control region 5 kb away from putative
enhancer region (PE+ 5 kb), with quantitative PCR (ChIP-
qPCR), we confirmed that the levels of H3K27ac were sig-
nificantly higher in the 3080 line than the 5199 line (Fig. 2b),
whereas an equivalent level of H3K4me1 within the putative
enhancer was detected between these two lines. The discrepancy
in H3K4me1 at the putative enhancer detected by ChIP-qPCR
and ChIP-seq may be due to the fact that H3K4me1 can be
detected in the distal region. Alternatively, this putative enhancer
could be in primed state, characterized by the presence of
H3K4me1 and absence of H3K27ac in the 5199 line. Collectively,
these results suggest that a putative enhancer is activated in the
TMZ-resistant 3080 line and potentially drives MGMT
expression.
Enhancers are regulatory elements that can promote gene
expression. Therefore, we first tested whether this region can
enhance transcription of a luciferase reporter gene. We cloned
ten DNA fragments (R1–R10), each 1–2 kb in size, spanning the
13.5 kb H3K27ac peak region, in front of an SV40 promoter-
driven firefly luciferase reporter. Each reporter construct was co-
transfected with a pRL Renilla luciferase control reporter
construct, which constitutively expresses Renilla luciferase to
allow for normalization of transfection efficiency. While R1, R2,
R6, R7, R9, and R10 significantly stimulated transcription
compared to pGL3 vector control (Supplementary Fig. 2), only
the 1.5 kb R7 fragment, localized in the second H3K27ac peak
region, exhibited significantly higher activity in the 3080 line
compared to 5199 (Fig. 2c). These results suggest that R1, R7, and
R10 regions have enhancer activity in luciferase reporter assays,
with the R7 fragment exhibiting differential effect on the reporter
in the 3080 compared to 5199.
Enhancers typically contact with their cognate gene promoters
through long-range interactions30–32. We next tested whether the
putative enhancer interacts with the MGMT promoter using the
chromatin conformation capture (3C) assay (Fig. 2d). In 3080
cells, a strong interaction between K-M enhancer and MGMT
promoter was identified. The fourth test fragment (F4), which
overlaps with the R7 region tested in the reporter assay, displayed
significantly higher interaction frequency with the MGMT
promoter compared to the neighboring DNA fragments. More-
over, the interaction frequency between the F4 fragment and the
MGMT promoter in the 5199 line lacking MGMT expression was
significantly lower than the 3080 line, supporting the idea that the
putative K-M enhancer region specifically interacts with the
MGMT promoter in the 3080 line. Therefore, the 1.5 kb region
located 560 kb away from the MGMT promoter has character-
istics of an active enhancer (surrounded by nucleosomes with
high H3K27ac and H3K4me1, transcription enhancement, and
interaction with promoter). The differential activity between the
placebo 5199 line and the TMZ-resistant 3080 line further
underscored the idea that this enhancer was only activated in the
3080 line to stimulate MGMT transcription, even in the presence
of a methylated MGMT promoter.
Enhancer activation in PDX lines and primary tumor samples.
In addition to the 3080 line, we have detected MGMT protein
expression in four MGMT promoter hypermethylated xenograft
lines previously. To investigate whether the enhancer was acti-
vated in any of these MGMT-expressing and promoter-
methylated PDX lines, we analyzed H3K4me1 and H3K27ac
using ChIP-qPCR in eight MGMT promoter-methylated PDX
lines including four PDX lines expressing MGMT (GBM43,
GBM64, GBM115, and GBM122) and four lines without MGMT
expression (GBM46, GBM59, GBM61, and GBM102) (Supple-
mentary Fig. 3a). H3K4me1 ChIP-qPCR analysis showed that six
PDX lines (GBM43, GBM64, GBM115, GBM46, GBM61, and
GBM102) had high levels of H3K4me1 at the enhancer region
compared to a fragment 5 kb away (Supplementary Fig. 3b).
H3K27ac ChIP-qPCR analysis indicated that of the six samples
with H3K4me1, three samples (GBM64, GBM115, and GBM46)
had higher levels of H3K27ac at the K-M enhancer region
compared to control locus (Supplementary Fig. 3c), suggesting
that the K-M enhancer is activated in these three lines. The
GBM46 line is a MGMT low-expressing line from a recurrent
tumor, whereas the two MGMT-expressed lines, GBM115 and
GBM64, are from primary and recurrent tumor, respectively, and
have high levels of MGMT expression. Although the levels of
H3K4me1 and H3K27ac enrichment at the K-M enhancer locus
Table 1 The top 10 nearby genes with the most altered Group-1 enhancers
Rank Gene symbol Associated fold change p Value Adjusted p value Full gene name
1 MGMT 15.63 <0.001 <0.001 O-6-methylguanine-DNA methyltransferase
2 ST18 5.64 0.086 1 Human suppression of tumorigenicity 18
3 WDFY4 4.32 0.206 1 WD repeat- and FYVE domain-containing
protein 4
4 C17orf50 4.32 0.894 1 Chromosome 17 open reading frame 50
5 WBSCR17 4.32 0.477 1 Williams–Beuren syndrome chromosome
region 17
6 ACTL8 3.32 0.952 1 Actin-like 8
7 MAP3K21 3.32 0.604 1 Mitogen-activated protein kinase kinase
kinase 21
8 SORCS3 3.32 0.775 1 Sortilin-related VPS10 domain-containing
receptor 3
9 BHLHA9 3.32 1 1 Basic helix-loop-helix family member A9
10 TTR 3.32 0.952 1 Transthyretin
Genes with the most elevated expression within the 1141 genes in Group-1 are listed in the table. Associated fold changes represent the fold change in gene expression in the 3080 subline over 5199 line
(as calculated by normalized RNA-seq reads in 3080 line divided by normalized RNA-seq reads in 5199 line). Genes are sorted by fold change and 10 genes with the highest fold change are presented in
the table. The p value and adjusted p value are also shown
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do not correlate with MGMT expression in GBM46 line, activa-
tion of the enhancers in two other MGMT promoter-methylated
PDX lines correlates with high levels of MGMT expression,
suggesting that enhancer activation is one explanation for the
discordance between MGMT promoter methylation and gene
expression in both primary and recurrent tumor lines.
To determine whether enhancer activation can also be detected
in primary tissues, we chose to analyze H3K4me1 and H3K27ac
at the enhancer locus in paired primary and recurrent GBM
tumors with a methylated MGMT promoter. Sixty-four paired
frozen patient tumor samples at Mayo Clinic were identified and
further filtered based on the presence of MGMT promoter
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hypermethylation, TMZ treatment prior to resection of recurrent
disease and the suitable tumor cell density and tissue quality to
yield three pairs for subsequent ChIP-qPCR analysis (Table 2).
Compared to the primary tumor, both H3K4me1 and H3K27ac
levels increased in the recurrent tumor from patient #1 (Fig. 3a,
b). In contrast, while H3K27ac increased slightly in the recurrent
tumor from patients #2 and #3, the enrichment of H3K4me1 was
not altered at their enhancer locus. Interestingly, we detected a
significant increase in MGMT expression in the recurrent tumor
from patient #1 compared to its matched primary tumor (Fig. 3c),
whereas MGMT expression was not significantly altered in
recurrent tumors from patients #2 and #3. Based on the
immunofluorescence staining, we estimated that the fraction of
MGMT-expressing cells increased from 4% in the primary tumor
of patient #1 to 24% in recurrent tumor of this patient. A similar
percentage of MGMT-expressing cells were also detected in the
3080 subline (Supplementary Fig. 4). The relatively low
percentage of MGMT-positive cells detected in patient #1 and
in 3080 subline is likely due to tumor heterogeneity and/or
relatively low sensitivity of MGMT immunofluorescence. Sup-
porting this idea, glioblastoma is known for its extensive
intratumor heterogeneity33. It has been shown previously that
only 1 out of 50 patient samples had over 50% MGMT-positive
cells, and most MGMT-expressed tumor samples have 10–50%
MGMT-positive cells34. The fraction of MGMT-expressing
proliferating cells was not increased in recurrent tumors of
patients #2 and #3 compared to their corresponding primary
tumors (Fig. 3d–f and Supplementary Fig. 5). Although the small
sample size precludes robust conclusions, the data suggest
activation of this enhancer may also drive the MGMT expression
in some recurrent tumors with MGMT promoter methylation. In
the future, it would be interesting to analyze the enhancer activity
in a larger cohort of patient samples at single cell levels.
Targeting p300 to the K-M enhancer increases MGMT
expression. The level of H3K27ac at the enhancers correlates with
enhancer activity and gene expression. Therefore, we tested
whether an increase in H3K27ac on nucleosomes surrounding the
enhancer element in MGMT low-expressing cells will affect
MGMT expression35. Briefly, a Flag-tagged nuclease deactivated
Cas9 (dCas9) protein was fused with p300 HAT domain36 and
was targeted to the enhancer locus using five-guide RNAs
(gRNAs) in cells with low levels of MGMT expression (Fig. 4a).
HEK293T cells were chosen first in this experiment due to their
high transfection efficiency. Successful targeting of dCas9 or
dCas9p300 Core fusion proteins to the K-M enhancer locus was
confirmed by Flag ChIP-qPCR (Fig. 4b). Moreover, we observed a
marked increase of H3K27ac at the K-M enhancer locus when
dCas9p300 Core fusion protein, but not dCas9 alone, was expressed
along with gRNAs (Fig. 4c). RT-PCR analysis indicated MGMT
transcription also increased dramatically in HEK293T cells when
targeting dCas9p300 Core to the enhancer region by CRISPR/dCas9
(Fig. 4d). Although expression of the dCas9p300 Core fusion pro-
tein alone without gRNAs slightly increased H3K27ac levels, this
increase did not significantly alter MGMT expression, suggesting
that a threshold level of H3K27ac is needed to alter the chromatin
state surrounding the enhancer and gene expression of MGMT.
We also observed a slight, but significant increase in MGMT
expression after we targeted dCas9p300 Core to the enhancer locus
in the 5199 line (Fig. 4e–g). Thus, the increased H3K27ac at
nucleosomes surrounding the K-M enhancer can stimulate
MGMT expression even in the presence of MGMT promoter
methylation.
Deletion of the enhancer results in reduced MGMT expression.
To directly determine whether the enhancer was essential for
MGMT expression, we used the CRISPR/Cas9 system37 to delete
a 3.3 kb region (chr10: 130,704,894–130,708,206) in the MGMT-
expressing SKMG3 glioblastoma cell line (Fig. 5a). Four inde-
pendent clones (three homozygous deletion clones and one wild-
type control clone) were isolated. The genotypes of those four
clones were identified by PCR and further confirmed by Sanger
sequencing (Supplementary Fig. 6a–b). Compared to parental
SKMG3 cells and wild-type control clone, MGMT transcription
and protein expression level were markedly reduced in enhancer-
deleted clones (Fig. 5b, c).
Next, we analyzed the TMZ sensitivity of SKMG3 clones using
the clonogenic assay. Compared to the parental SKMG3 line and
wild-type control clone, the enhancer-deleted clones were sig-
nificantly more sensitive to TMZ treatment, with a log-fold decrease
in IC50 from over 100 µM to less than 10 µM (Fig. 5d–f). The
sensitizing effect was not observed in the group pre-treated with the
MGMT inhibitor O6BG (Fig. 5e, f), indicating the change in TMZ
sensitivity was mechanistically linked to MGMT activity. Since this
TMZ concentration range is clinically achievable, these results
suggest that an efficient suppression of the enhancer activity could
be a strategy to overcome the emergence of TMZ resistance.
To further narrow down the location of the enhancer-
activating MGMT expression in SKMG3 cells, we designed an
additional guide RNA (g3) targeted at the middle of the other
two-guide RNAs used for the 3.3 kb deletion and generated two
different 1.5 kb deletions when combined with g1 or g2 guide
RNAs, respectively (Supplementary Fig. 7a). Depletion of the first
1.5 kb region (ch10: 130,704,894–130,706,549), named Del1
region, also resulted in a dramatic reduction in MGMT
suppression in SKMG3 cells (Fig. 5g), while deletion of the
Del2 region, the 1.8 kb region closer to the MGMT promoter, did
not cause a significant change in MGMT expression (Supple-
mentary Fig. 7b). This result further narrowed down the location
of K-M enhancer to a 1.5 kb region that lies about 560 kb away
from the MGMT promoter and is essential for MGMT
expression. Similar to larger deletion clones, SKMG3 cells with
Fig. 2 Delineation of a putative enhancer-associated with MGMT gene in 3080 subline. a IGV snapshots showing H3K4me1, H3K27ac, H3K4me3, and
H3K36me3 ChIP-seq reads density at the putative enhancer region, MGMT promoter, and gene body in 5199 (TMZ-sensitive) and 3080 (TMZ-resistant)
xenograft lines. b H3K4me1 (bottom left) and H3K27ac (bottom right) occupancy at the putative K-M enhancer in 5199 (parental) and 3080 (TMZ-
resistant) xenograft tumors were analyzed by ChIP-qPCR. Three different sets of primers (PE1-3) were designed to analyze against putative enhancer
region. A set of primers amplifying 5 kb away from the putative enhancer (PE+ 5 kb) was used as negative control. Top: magnified view of H3K27ac ChIP-
read peaks and the location of each primer set. c Effect of each fragment on transcription of luciferase reporter gene in 5199 and 3080 cells. Fragments
R1–R10 covering putative enhancer region (top) were cloned upstream of luciferase promoter (middle). The ChIP-seq peak covered by R7 region is labeled
in blue. Each construct was transfected into 5199 or 3080 cells along with a plasmid expressing Renilla luciferase. Firefly and Renilla luciferase activities
were measured 36 h after transfection. Luciferase activity was normalized to the Renilla luciferase activity (internal control) first and subsequently
normalized to an empty vector control. d Enhancer–promoter interaction analyzed by chromatin conformation capture (3C) assay. Relative
interaction frequency of each restriction fragment (F1–F6) was calculated as described in the experimental procedures and was plotted on genomic location
of the 3′ cutting site of each fragment (X axis). Values reported were derived from three biological repeats (*p < 0.05, **p < 0.01, Student’s t test). The
genomic region covered by H3K27ac peak is labeled in orange, location of R7 fragment was colored in blue to highlight the overlap with the F4 fragment
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Fig. 3 Enhancer activity and MGMT expression in three pairs of GBM patient samples. a, b Relative occupancy of H3K4me1 (a) and H3K27ac (b) in the K-
M enhancer region in primary and matched recurrent tumors from three GBM patients was analyzed by ChIP-qPCR using primers described in Fig. 2.
cMGMT expression level in each tumor was analyzed by immunofluorescence. The MGMT signal (area × average intensity) from 100 individual nuclei was
measured and one-way ANOVA was used for the calculation of significance (****p < 0.0001, ns not significant, n= 100) d Analysis of MGMT expression
in proliferating tumor cells. Multicolor immunofluorescence was performed using antibodies against CD45, Ki67, and MGMT. Proliferating tumor cells
(Ki67 staining without CD45 staining) were identified and the percentage of MGMT-positive proliferating cells was calculated. Two-tail paired Student's
t test was used for calculation of significance (*p < 0.05). e, f Representative images showing co-localization of MGMT and Ki67 in tissue sections from
primary tumor (e) and recurrent tumor (f) obtained from patient #1
Table 2 Treatment and survival information for patients who provided primary and recurrent tumor samples
Demographics Patient 1 Patient 2 Patient 3
Age 64 67 68
Treatment Standard chemo-radiotherapy Standard chemo-radiotherapy Standard chemo-radiotherapy
Initial progression-free survival 11 months 21 months 23 months
Initial treatment at progression TMZ TMZ TMZ
Interval between primary and recurrent tumor
resection
17 months 29 months 38 months
Overall survival 29 months 55 months 43 months
The patient demographics and treatment records were summarized in this table
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the 1.5 kb deletion also showed increased TMZ sensitivity, but to
lesser degree than deletion clones with the 3.3 kb region (Fig. 5h),
suggesting that the second half of the 3.3 kb region also
contributes to the regulation of MGMT expression. Finally, we
obtained one clone with the 1.5 kb Del1 in 3080 line
(Supplementary Fig. 7e), and deletion of this fragment in the
3080 cells also resulted in reduced MGMT expression (Fig. 5i)
and increased TMZ sensitivity in vitro (Fig. 5j). Together, these
results fully demonstrate that this fragment can serve as the
MGMT enhancer.
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Effect of the enhancer deletion on Ki67 expression. K-M
enhancer may not only regulate protein expression but also
promotes proliferation. During clonogenic assay analysis, the
untreated deletion clones formed smaller colonies suggestive of
impaired proliferation. This observation was confirmed by a
proliferation assay, showing a clear decrease in proliferation rate
in two out of three 3.3 kb deletion and all 1.5 kb deletion SKMG3
clones (Fig. 6a–d and Supplementary Fig. 7c–d). However, cell
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cycle appears to be normal in the enhancer-deleted clones. This
suggests that the enhancer may also regulate expression of genes
involved in proliferation in addition to MGMT.
MKI67 is a gene encoding the nuclear protein Ki67, which is
a proliferation marker for many tumors including GBM
(Supplementary Fig. 8). Because MKI67 is another gene
localized close to the enhancer, we first analyzed the published
Hi-C data sets38 to determine whether the MKI67 gene
localized in the same topologically associating domain (TAD)
withMGMT. We found thatMIK67 resided in the same TAD as
MGMT and the enhancer in neuroblastoma cells (Fig. 6b) and
localized at the left boundary of the TAD domain-containing
MGMT in cortical and subcortical plate cells (Fig. 6c). Since the
TAD boundaries are not well defined, these results suggest that
the K-M enhancer, MKI67 and MGMT may be in the same
TAD. We then analyzed Ki67 expression in the enhancer
deletion clones. We observed that two SKMG3 clones with the
3.3 kb deletion exhibited a significant decrease of Ki67
expression as well as reduced proliferation (Fig. 6d, e). Tumor
growth rate and Ki67 expression were also reduced in the 3080
Del1 deleted clone (Fig. 6f, g). However, we noticed that in all
these clones with the deletion of the enhancer element, the
expression of MGMT was affected more than Ki67. Collectively,
our results indicate that the K-M enhancer is the enhancer for
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both MGMT and Ki67, which in turn regulates TMZ sensitivity
and possibly cell proliferation.
Discussion
Previous studies have associated MGMT hypermethylation with
gene silencing39. However, discordance between promoter
hypermethylation and MGMT suppression is observed both
in vitro and in vivo14,40. Here we identify a distal enhancer (K-M
enhancer) regulating MGMT expression. Surprisingly, the acti-
vated enhancer appears to overcome the promoter hypermethy-
lation and drives the MGMT expression. Therefore, the
mechanism revealed in this study might contribute to the
reported discordance between MGMT promoter methylation and
expression in at least a fraction of tumors. Deletion of the K-M
enhancer reduces MGMT and Ki67 expression, decrease cell
proliferation, and sensitizes cells to TMZ to a clinical relevant
level, which suggests potential therapeutic benefits of targeting
enhancer activity. Beyond MGMT, a set of 1141 putative
enhancers were activated in the TMZ-resistant 3080 line (Sup-
plementary Data 2), which raises the possibility that multiple
enhancers are altered in response to TMZ therapy, some of which
contribute to the emergence of drug resistance.
MGMT expression is mechanistically linked to TMZ resistance,
and the discordance between promoter methylation and protein
expression observed in a subset of patients limits the prognostic
accuracy of methylation assessment. Despite the overt require-
ment for protein expression of MGMT to repair TMZ-induced
damage, MGMT promoter methylation is a more accurate pre-
dictor of TMZ resistance as compared to either RNA or protein
expression. In this study, we demonstrate that activation of the K-
M enhancer can drive MGMT expression despite promoter
methylation. Moreover, a subset of MGMT hypermethylated
GBM PDX lines with K-M enhancer activation expresses basal
MGMT protein in association with de novo TMZ resistance.
These observations may help explain why approximately a
quarter of newly diagnosed MGMT hypermethylated GBM
patient progress within the first few months of TMZ therapy41.
Finally, the activation of the K-M enhancer during resistance
emergence without corresponding changes to MGMT promoter
methylation may partially explain the poor prognostic perfor-
mance of methylation status in recurrent GBM. Mechanisms of
inherent and acquired TMZ resistance extend beyond MGMT
regulation. Therefore, we speculate that in addition to genetic
mutations, enhancer alterations through changes in chromatin
states likely contribute both to intrinsic and acquired TMZ
resistance.
Beyond enhanced prognostic accuracy, therapeutic suppression
of the K-M enhancer could be used to delay the emergence of
TMZ resistance and/or sensitize-resistant patients to TMZ. We
showed that epigenetic activation of the K-M enhancer drives
TMZ resistance, while enhancer deletion results in greater TMZ
sensitivity. Therefore, blocking enhancer activation may prevent
enhancer-driven TMZ resistance. A similar concept has been
tested in breast and lung cancer, where epigenetic inhibitors
successfully prevented chemoresistance emergence driven by
epigenetic alterations of gene promoters42,43. If successful,
enhancer inhibition may prevent or delay the emergence of TMZ
resistance and produce more durable responses for GBM patients,
which may make a critical improvement in survival. Furthermore,
deletion of the enhancer reduces proliferation and sensitizes cells
to TMZ. This indicates that blocking the K-M enhancer activity
potentially not only enhances TMZ response, but also reduces
aggressiveness of otherwise TMZ-resistant tumors. In principle,
enhancer activity can be blocked by several methods including
blocking the recognition of acetylated histones and inhibition of
histone acetyltransferase activity. For example, both bromodo-
main inhibitors (BETi), which blocks H3K27ac recognition by
bromodomain-containing proteins, and histone acetyltransferases
inhibitors (HATi), which reduce enhancer activity by inhibiting
H3K27 acetylation, can effectively inhibit enhancer-driven tran-
scription activation with acceptable toxicity44–46. However, no
study has been done to combine BETi or HATi with TMZ
treatment. Similarly, a recent study demonstrated that the CDK7/
12 inhibitor THZ1 prevents active enhancer formation at genes,
which inhibit the emergence of chemoresistance in multiple
cancer lines47. CDK7 and CDK12 are two genes that regulate Pol
II-mediated gene transcription. Therefore, we propose that
combination therapy with TMZ and a BETi, HATi, or CDK7/12i,
may delay the emergence of TMZ resistance in responsive tumors
and potentially sensitize drug-resistant tumors to TMZ.
In contrast to BET and HAT inhibitors, histone deacetylase
inhibitors (HDACi), which globally increase histone acetylation
including H3K27ac, may promote the emergence of TMZ resis-
tance by activating the K-M enhancer. Supporting this idea, we
observed that combination treatment of SAHA, an FDA-
approved HDACi, with TMZ specifically promotes elevation of
MGMT expression as a mechanism of TMZ resistance14. Our
enhancer activation model suggests that acetylation of both the
MGMT promoter and the K-M enhancer significantly contributes
to this effect. Thus, any future designs of treatment strategies that
combine TMZ and histone deacetylase inhibitors should be
approached with appropriate caution.
Beyond mediating MGMT expression and TMZ sensitivity,
enhancer deletion was associated with reduced proliferation in
five out of six enhancer-deleted clones, suggesting that K-M
enhancer inactivation may also reduce tumor growth. Interest-
ingly, unlike the observed increase in MGMT expression, Ki67
expression in 5199 was similar to 3080 line, indicating differential
influence of the K-M enhancer on the two most proximal genes,
MGMT and MKI67. Indeed, MGMT expression was affected
more dramatically than Ki67 in each of the enhancer deletion
clones we tested. One likely explanation is that this enhancer is a
key regulator of MGMT expression in all cells, while K-M
enhancer modulation of the MKI67 promoter is cell type specific.
Potentially, sequence differences within the K-M enhancer region
may differentially affect binding of transcriptional activators and/
or repressors that result in altered enhancer activity within dif-
ferent cells. Future studies are needed to catalog the transcription
factors that bind to the K-M enhancer and more fully characterize
sequence variations within this region. Regardless of mechanism,
the dual regulation of both MGMT and Ki67 by the K-M
enhancer highlights the potential for this enhancer to influence
both TMZ efficacy and tumor proliferation.
In summary, our study reveals a previously undocumented
enhancer that, when activated, promotes MGMT expression and
TMZ resistance in different cell lines, even in the presence of
promoter methylation. This enhancer likely also regulates the
expression of Ki67 as well as tumor proliferation. These findings
suggest that inhibition of enhancer activity is a plausible strategy
for the development of therapies and that an assessment of
enhancer activation states might be useful as a predictive
biomarker.
Methods
Cell culture. GBM cell line SKMG3 (provided by Dr. David James) and HEK293T
cell line procured from ATCC were maintained in DMEM (CORNING, 10-013-
CV) supplemented with 10% fetal bovine serum (Millipore Sigma, TMS-013-B)
and 1% penicillin–streptomycin (CORNING, 30-001-CI).
GBM xenograft sublines GBM12 5199 and GBM12 3080 previously generated
by our lab were used to isolate primary cells. Primary cells from xenograft tissues
were cultured in StemPro NSC media and supplements (ThermoFisher, A1050901)
according to the manufacturer’s instructions.
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All cells are tested for mycoplasma contamination each month. All cells used in
this paper are mycoplasma free.
Xenograft tumors. Frozen tumor tissues from xenografts established from pri-
mary GBMs (GBM43, GBM59, GBM61, GBM115, and GBM122) and those from
recurrent GBMs (G46, G64, and G102) were previously generated by our lab48.
Paired patient samples. Studies involving patient samples were approved by the
Mayo Clinic Institutional Review Board (IRB number 09-003015). Paired (primary
and recurrent) GBM frozen tissue samples collected from consented patients, who
had hypermethylated MGMT promoter at primary diagnoses and received stan-
dard TMZ-based treatment, were obtained from Mayo Clinic Neuro-Oncology
tissue bank. A total of three pairs of frozen tumors with high-tumor cellularity
(>80%), large sample size (>30 mg), and hypermethylated MGMT promoter were
selected. Tissues were cryosectioned and subjected to parallel immunofluorescence
and ChIP-qPCR analyses. Tumor samples for ChIP-qPCR were collected by
scraping the tumor dense areas from the tissue sections and used for ChIP assays as
described in references [49–51].
Antibodies. Antibodies against MGMT (AF3794,1:1000) and α-tubulin (12G10,
1:1000) were used in western blotting analysis.
Antibodies against H3K4me1 (Abcam, Ab8895), H3K27ac (Abcam, Ab4729),
H3K9ac (Abcam, Ab4441), H3K4me3 (Abcam, Ab8580), H3K9me3 (Active Motif,
39161), H3K36me3 (Active Motif, Cat #61101), and Flag (Sigma-Aldrich,
11583816001) were used for chromatin immunoprecipitation assay.
Monoclonal antibodies against CD45 (13917,1:100), MGMT (MAB16200,
1:100), Ki67 (14-5698-82, 1:100), and conjugated Alexa Fluor 488 labeled goat anti-
rabbit IgG (111-545-144, 1:200), Alexa Fluor 594 labeled goat anti-mouse IgG
(A11032, 1:200) and Cy5 labeled goat anti-rat IgG (112-175-167, 1:200) were used
for immunofluorescence staining.
Western blot assay. Protein samples are separated using gel electrophoresis and
transferred onto a nitrocellulose membrane. The membrane is blocked with 5%
milk, probed by primary antibodies (1:1000), and subsequently probed by corre-
sponding secondary antibody (1:5000).
RNA isolation, reverse transcription, and real-time PCR. RNA was extracted
with RNeasy Plus kit (Qiagen, #74134) according to the manufacturer’s instruc-
tions. Reverse transcription of mRNA was performed using SuperScript™ III
Reverse Transcriptase (Invitrogen, 18080-085). For real-time PCR analysis, 1 µl of
cDNA (25 ng of starting RNA) was amplified per reaction using the iTaq Universal
SYBR Green Supermix (Bio-Rad, 172–5124) and the Bio-Rad CFX qPCR system.
Primers for real-time qPCR analysis were listed in supplemental table (Supple-
mentary Table 2).
RNA-seq. Total RNA was extracted as described above. The RNA quality was
further evaluated using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA).
The Illumina TrueSeq RNA Sample preparation Kit v.4.1 (Illumina Inc., San Diego,
CA) was used to prepare cDNA libraries from 2 µg of total RNA for RNA-seq.
Individual barcoded libraries were analyzed using Agilent 2100 Bioanalyzer (Agi-
lent technologies). Sequencing was carried out on an Illumina HiSeq 2000 machine
(Illumina) at Mayo Clinic Medical Genomic Facility.
MS-PCR. DNA was extracted from frozen tissues or cells using Blood & Cell
Culture DNA Mini Kit (Qiagen, #13323). Isolated genomic DNA was bisulfite
treated with EZ DNA methylation Gold kit (Zymo Research, #11-335B). The
modified DNA was quantified by PCR. One pair of primer (MS-M-F/R) was used
to PCR-methylated MGMT promoter. Another pair of primer (MS-U-F/R) was
used to PCR unmethylatedMGMT promoter. The sequences for PCR primers were
listed in supplemental table (Supplementary Table 2).
Chromatin immunoprecipitation. A total of 1 × 106 cells or 15 mg homogenized
frozen tissues were fixed with 1% paraformaldehyde at room temperature for
10 min, quenched with 0.125 M glycine, and lysed for 10 min on ice. The lysate was
digested with MNase (NEB, Cat#M0247S) at 2000 gel unit/ml final concentration
at 37 °C for 20 min and sonicated 15 cycles (30 s on, 30 s off) under high power
using a Diagenode Bioruptor. Crosslinked DNA was immunoprecipitated with 2 µg
antibody at 4 °C overnight, pulled down by protein G beads, washed, reverse
crosslinked and purified for qPCR, and high-throughput sequencing analysis.
For ChIP-qPCR analysis, both input and immunoprecipitated DNA were
quantified by real-time PCR with primers listed in supplemental table
(Supplementary Table 2). DNA quantity for each ChIP sample was normalized
against input DNA.
For ChIP-seq samples, after DNA purification ChIP-seq DNA libraries were
prepared with the Ovation Ultralow DR Multiplex system (NuGEN). The DNA
libraries were sequenced using the 51 bp paired-end sequencing method by an
Illumina Hi-seq 2000.
ChIP-seq analysis. Raw reads from Illumina Hi-seq 2000 were aligned to the
human genome (hg19) using Bowtie2 software with default parameters. Only
uniquely mapped reads were used for secondary analysis. The ChIP-seq peaks were
identified by MACS2 using the default calling parameter. Cutoff values for the
p value was set to 0.001. Genome-wide read coverage was calculated by BEDTools
and visualized using Integrative Genomics Viewer. The reads density scan was
performed by in-house Perl programs using the traditional normalization method:
reads per kilobase per million mapped reads (RPKM).
For cluster analysis, first genomic regions with high H3K4me1 and low
H3K4me3 occupancy in 5199 and 3080 cells were selected. H3K4me1 peaks were
merged if their distance is less than 500 bp. The log2
H3K4me1ð3080Þ
H3K4me1ð5199Þ and log2
H3K27acð3080Þ
H3K27acð5199Þ on those merged peaks were used for unsupervised k-means cluster
analysis.
Pathway analysis. The Group-1 genes identified from cluster analysis were
imported into ingenuity pathway analysis (IPA) program. A list of affected path-
ways was calculated based on default setting.
Reporter assay. DNA fragments tested in a reporter assay are named as reporter
fragments (R1–R10). Those fragments were inserted upstream of the SV40 pro-
moter and Firefly luciferase in a pGL3 promoter vector. For each transfection
reaction, 100 ng control plasmid expressing Renilla luciferase and 300 ng Firefly
luciferase construct were co-transfected into 2 × 105 cells in a 24-well plate well.
After 24 h, luciferase activities were measured by the Dual-Luciferase Reporter
Assay System (Promega, E1910).
Chromatin conformation capture assay. The experiment was performed as
described [52]. Briefly, cells were crosslinked with 1% formaldehyde at room
temperature for 10 min, quenched with 0.125 M glycine, lysed, and treated with
600 U HindIII (NEB, #R3104) at 37 °C overnight followed by a 4 h ligation with T4
enzyme (NEB, M0202L) at 16 °C. Ligated products were quantified in triplicate by
TaqMan real-time PCR. Probes and primers (listed in Supplementary Table 2)
were designed by using primer blast provided by NCBI. Control 3C template was
generated by using two bacterial artificial chromosomes (BACs), 656G14 and
1125P18, which together encompass putative K-M enhancer and MGMT promoter
regions. Equimolar of the two BACs were digested with HindIII and ligated. The
ligation product from BAC control was used for normalization. The relative
interaction frequency was calculated as: 2Ct BACð ÞCtð3CÞ
Immunofluorescence. Since the enhancer is localized betweenMKI67 andMGMT,
we evaluated both MGMT and Ki67 expression in patient samples using immu-
nofluorescence. OCT-embedded patient tumor tissues were sectioned at 5-micron
thickness. Slides were fixed by 4% paraformaldehyde at 4 °C for 10 min, penetrated
with PBS plus 0.25% Triton X-100 for 10 min, and then treated with steam TBS
antigen retrieval buffer at pH 9.0 for 60 min. One hour primary antibody incu-
bation (1:100 dilution) was performed at room temperature followed by 1 h sec-
ondary antibody incubation (1:200 dilution). Slides were rinsed, dehydrated, and
mounted with Prolong Gold antifade mounting media with DAPI (Invitrogen, Cat
#P36935) and analyzed by confocal microscopy (LSM 780; ×63 objective lenses).
MGMT and Ki67 were considered positive when uniform staining was detected in
cell nuclei. CD45 was considered positive when cytoplasmic staining was detected.
The signal intensity for each cell was quantified in ImageJ program. The area of
each nucleus was determined by DAPI staining. The total signal for each nucleus
was calculated as: signal= area × average signal intensity. The total signal for 100
nuclei from each slides were quantified and plotted.
The investigator was blinded to sample allocation during immunofluorescence
image collection and counting.
Guide RNA design and cloning. All guide RNAs were designed by using MIT
CRISPR Design website (http://crispr.mit.edu). To minimize potential off-target
effects of guide RNA, only high-score guide RNAs (score >85) were used. Guide
RNA sequences are listed in Supplementary Table 3.
Guide RNAs used in the CRISPR/dCas9 system were cloned into lentiGuide
puro vector (Addgene, Plasmid #52963)53. Guide RNAs used in CRISPR/Cas9 were
cloned into lentiCRISPRv2 vector using the same protocol.
Enhancer activation by CRISPR/dCas9p300 Core system. A total of 5199 cells
were infected with a mixture of virus containing five-guide RNAs while
HEK293T cells were co-transfected with a pooled guide RNA containing five-guide
RNA constructs. Both 5199 cell and HEK293T cells are transfected with a pcDNA-
dCas9-p300 Core (or control dCas9) plasmid (Addgene, Plasmid #61357). Pur-
omycin selection was performed 24 h post transfection. Targeting of dCas9p300 Core
protein was confirmed by Flag ChIP-qPCR assay at 72 h post transfection.
Enhancer activity and MGMT transcript were assessed by H3K27ac ChIP-qPCR
and RT-PCR, respectively. Primers used for ChIP-qPCR and RT-PCR assay are
listed in Supplementary Table 2.
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CRISPR/Cas9-mediated genomic deletion. Guide RNAs were cloned into len-
tiCRISPR v2 vector (Addgene, Plasmid #52961). Lentiviruses for CRISPR editing
were produced in HEK293T cells. In the genomic deletion experiment, SKMG3
and 3080 cells were infected with equal amount of lentivirus carrying two-guide
RNAs flanking the region to be deleted, followed by clonal selection under pur-
omycin and clone expansion. Paired guide RNAs g1/g2 were used to generate
larger deletion, while paired guide RNAs g1/g3 and g2/g3 were used to generate the
smaller deletions, respectively. PCR amplification was used for genotypic char-
acterization of putative deletion clones. The sequence of those primers is listed in
supplemental table (Supplementary Table 2). The PCR products of positive clones
with homozygous deletion were validated by Sanger sequencing. The 3080 deletion
clones consistently grew poorly in culture. For this reason, the initial deletion
clones were implanted into the flank of nude mice, and from this effort, we
obtained a single homozygous clone that subsequently grew and could be tested
in vitro. This work is conducted under relevant ethical regulations of Mayo Clinic
Institutional Animal Care and Use Committee (IACUC protocol number:
A00003130-17).
Clonogenic assay. Clonogenic assays were performed to assess the effect of the
deleted enhancer on TMZ sensitivity. Briefly, SKMG3 parental cells and enhancer
deletion clones were plated in 6-well plates (250 cells/well), treated with graded
concentration of TMZ in presence or absence of O6BG and were cultured for
2 weeks. Colonies were fixed and stained with crystal violet (0.005% (w/v) Crystal
violet, 25% (v/v) Methanol). Colonies with >50 cells were manually counted, IC50
values were calculated in GraphPad Prism 7 using a multiparametric nonlinear
regression model.
Neurosphere assay. Primary cells suspended in StemPro NSC media were plated
in triplicate in 96-well plates (500 cells per well) and treated with graded con-
centration of TMZ (0–1000 µM/L final concentration). Intact neurospheres con-
taining more than 50 cells were counted after 15 days. Cell viability was calculated
relative to DMSO control. IC50 values were calculated as above.
Cell proliferation assay. IncuCyte Live Cell Analysis system was used to measure
cell proliferation of SKMG3 wild-type clone and K-M enhancer-deleted clones.
Each clone was plated into triplicate wells of a 96-well plate at 500 cells per well.
The percent confluency for each well was measured every 4 h for 6 days. The
confluency data were used to calculate a proliferation rate as the fold change in
confluency each day as compare to Day 0.
CellTiter-Blue® Cell Viability Assay kit (CTB) was used to measure cell viability
for SKMG3 and SKMG3-Del1 clones. Each clone was plated into triplicate wells of
a 96-well plate at 1000 cells per well. Cell metabolism rate was measured every
other day according to kit manufacturer’s instruction. Fluorescence signal was read
by GloMax®-Muti Microplate Multimode Reader with excitation at 560 nm and
emission at 590 nm.
Flank tumor injection. A total of 1 × 106 cells were injected into the flank of
athymic mice. Tumors were measured with calipers three times a week, and mice
were killed and tumors harvested when the tumors exceed 2000 mm3.
Statistical analysis. ChIP-qPCR analysis for patient samples was performed only
once due to limited tissue availability. For all other results, three independent
experiments were performed.
A two-tailed Student’s t test was used to establish statistical significance between
control and testing group for all comparison between two data sets. One-way
ANOVA was used for MGMT and Ki67 signal intensity comparison analysis.
Data availability. The data that support the findings of this study are available
from the article and Supplementary Information Files, or from the corresponding
author on request. ChIP-seq and RNA-seq data sets used this study are publically
available in the GEO database, under the GSE accession number GSE113816.
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